Literature DB >> 20843714

HFE gene mutations in patients with primary iron overload: is there a significant improvement in molecular diagnosis yield with HFE sequencing?

Paulo C J L Santos1, Alexandre C Pereira, Rodolfo D Cançado, Isolmar T Schettert, Tiago J P Sobreira, Paulo S L Oliveira, Rosario D C Hirata, Mario H Hirata, Maria Stella Figueiredo, Carlos S Chiattone, Jose E Krieger, Elvira M Guerra-Shinohara.   

Abstract

Rare HFE variants have been shown to be associated with hereditary hemochromatosis (HH), an iron overload disease. The low frequency of the HFE p.C282Y mutation in HH-affected Brazilian patients may suggest that other HFE-related mutations may also be implicated in the pathogenesis of HH in this population. The main aim was to screen for new HFE mutations in Brazilian individuals with primary iron overload and to investigate their relationship with HH. Fifty Brazilian patients with primary iron overload (transferrin saturation>50% in females and 60% in males) were selected. Subsequent bidirectional sequencing for each HFE exon was performed. The effect of HFE mutations on protein structure were analyzed by molecular dynamics simulation and free binding energy calculations. p.C282Y in homozygosis or in heterozygosis with p.H63D were the most frequent genotypic combinations associated with HH in our sample population (present in 17 individuals, 34%). Thirty-six (72.0%) out of the 50 individuals presented at least one HFE mutation. The most frequent genotype associated with HH was the homozygous p.C282Y mutation (n=11, 22.0%). One novel mutation (p.V256I) was indentified in heterozygosis with the p.H63D mutation. In silico modeling analysis of protein behavior indicated that the p.V256I mutation does not reduce the binding affinity between HFE and β2-microglobulin (β2M) in the same way the p.C282Y mutation does compared with the native HFE protein. In conclusion, screening of HFE through direct sequencing, as compared to p.C282Y/p.H63D genotyping, was not able to increase the molecular diagnosis yield of HH. The novel p.V256I mutation could not be implicated in the molecular basis of the HH phenotype, although its role cannot be completely excluded in HH-phenotype development. Our molecular modeling analysis can help in the analysis of novel, previously undescribed, HFE mutations.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20843714     DOI: 10.1016/j.bcmd.2010.08.008

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  7 in total

1.  Non-HFE hemochromatosis.

Authors:  Paulo Caleb Júnior de Lima Santos; Carla Luana Dinardo; Rodolfo Delfini Cançado; Isolmar Tadeu Schettert; José Eduardo Krieger; Alexandre Costa Pereira
Journal:  Rev Bras Hematol Hemoter       Date:  2012

Review 2.  Molecular diagnostic and pathogenesis of hereditary hemochromatosis.

Authors:  Paulo C J L Santos; Jose E Krieger; Alexandre C Pereira
Journal:  Int J Mol Sci       Date:  2012-02-01       Impact factor: 6.208

3.  SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group.

Authors:  Paulo C J L Santos; Renata A G Soares; Raimundo M Nascimento; George L L Machado-Coelho; José G Mill; José E Krieger; Alexandre C Pereira
Journal:  BMC Med Genet       Date:  2011-10-12       Impact factor: 2.103

4.  Evaluation of a high throughput method for the detection of mutations associated with thrombosis and hereditary hemochromatosis in Brazilian blood donors.

Authors:  Vivian Dionisio Tavares Niewiadonski; Juliana Vieira Dos Santos Bianchi; Cesar de Almeida-Neto; Nelson Gaburo; Ester Cerdeira Sabino
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

5.  Effects of Iron Overload on the Activity of Na,K-ATPase and Lipid Profile of the Human Erythrocyte Membrane.

Authors:  Leilismara Sousa; Israel J P Garcia; Tamara G F Costa; Lilian N D Silva; Cristiane O Renó; Eneida S Oliveira; Cristiane Q Tilelli; Luciana L Santos; Vanessa F Cortes; Herica L Santos; Leandro A Barbosa
Journal:  PLoS One       Date:  2015-07-21       Impact factor: 3.240

6.  Quality of life scores differs between genotypic groups of patients with suspected hereditary hemochromatosis.

Authors:  Paula Fernanda Silva Fonseca; Rodolfo Delfini Cançado; Flavio Augusto Naoum; Carla Luana Dinardo; Guilherme Henrique Hencklain Fonseca; Sandra Fatima Menosi Gualandro; José Eduardo Krieger; Alexandre Costa Pereira; Pierre Brissot; Paulo Caleb Junior Lima Santos
Journal:  BMC Med Genet       Date:  2018-01-05       Impact factor: 2.103

7.  HFE hemochromatosis: an overview about therapeutic recommendations.

Authors:  Rodolfo D Cancado; Aline Morgan Alvarenga; Paulo Caleb Jl Santos
Journal:  Hematol Transfus Cell Ther       Date:  2021-11-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.